An effective cancer blood biomarker screening strategy must distinguish aggressive from nonaggressive tumors at an early, intervenable time. However, for blood-based strategies to be useful, the quantity of biomarker shed into the blood and its relationship to tumor growth or progression must be validated. To study how blood biomarker levels correlate with early-stage viable tumor growth in a mouse model of human cancer, we monitored early tumor growth of engineered human ovarian cancer cells (A2780) implanted orthotopically into nude mice. Biomarker shedding was monitored by serial blood sampling, whereas tumor viability and volume were monitored by bioluminescence imaging and ultrasound imaging. From these metrics, we developed a mathematical model of cancer biomarker kinetics that accounts for biomarker shedding from tumor and healthy cells, biomarker entry into vasculature, biomarker elimination from plasma, and subject-specific tumor growth. We validated the model in a separate set of mice in which subject-specific tumor growth rates were accurately predicted. To illustrate clinical translation of this strategy, we allometrically scaled model parameters from mouse to human and used parameters for PSA shedding and prostate cancer. In this manner, we found that blood biomarker sampling data alone were capable of enabling the detection and discrimination of simulated aggressive (2-month tumor doubling time) and nonaggressive (18-month tumor doubling time) tumors as early as 7.2 months and 8.9 years before clinical imaging, respectively. Our model and screening strategy offers broad impact in their applicability to any solid cancer and associated biomarkers shed, thereby allowing a distinction between aggressive and nonaggressive tumors using blood biomarker sampling data alone. Cancer Res; 77(10); 2570–84. ©2017 AACR.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2rhbJ01
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers British Journal of Cancer 116, 1425 (23 May 2017). ...
-
Publication date: April 2017 Source: European Journal of Cancer, Volume 75 Author(s): A. Ieni, G. Angelico, P. Zeppa, G. Tuccari fro...
-
BACKGROUND AND PURPOSE: Feasibility of brain atrophy measurement in patients with MS in clinical routine, without prior standardization o...
-
Objective A systematic review and meta-analysis to investigate the impact of electronic nicotine delivery systems (ENDS) and/or electronic n...
-
Publication date: October 2017 Source: International Journal of Biological Macromolecules, Volume 103 Author(s): Shehwaz Anwar, Hina Youn...
-
Publication date: Available online 13 May 2017 Source: Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms Author(s): Ping Li...
-
Rejuvenation Research , Vol. 0, No. 0. from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2EFILxo via I...
-
Letter to the editor of Acta Neurochirurgica: simultaneous pericranial and nasoseptal "double-flap" reconstruction after comb...
-
Related Articles Characteristic MR Imaging Findings of the Neonatal Brain in RASopathies. AJNR Am J Neuroradiol. 2018 Apr 05;:...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου